Aptevo Therapeutics
APVO · Nasdaq · United States
Share price · APVO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when APVO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-16.0%
- 11 Nov 2026-29.6%
Nothing announced by APVO that day or the session before.
- 27 Oct 2026-14.7%
- 3 Sep 2026-34.2%
- 2 Sep 2026+11.1%
Nothing announced by APVO that day or the session before.
- 14 Aug 2026-13.5%
- 12 Aug 2026-15.4%
Nothing announced by APVO that day or the session before.
- 21 Jul 2026-7.0%
Nothing announced by APVO that day or the session before.
- 14 Jul 2026+11.3%
Nothing announced by APVO that day or the session before.
- 9 Jul 2026-12.4%
Nothing announced by APVO that day or the session before.
Share of unusual movement by asset
For each asset, the share of APVO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
ALG.APV-527No recent activity | Phase 1/2 | 4-1BB (CD137) x 5T4Multispecific antibody | Solid Tumors |
| Phase 1 | CD123 x CD3Biologic (subtype unspecified) | Acute Myeloid Leukemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $3.7M | $9.8M | $6.4M-$5.5M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | — | $15M | — | report ↗ |
| 2025-Q3 | — | $4.0M | $21M | $7.5M-$6.7M operating cash flow | report ↗ |
| 2025-Q2 | — | $3.3M | $9.4M | $6.2M-$7.1M operating cash flow | report ↗ |
| 2025-Q1 | — | $3.6M | $2.1M | $6.4M-$6.6M operating cash flow | report ↗ |
| 2024-Q3 | — | $3.1M | $7.8M | $5.1M-$5.2M operating cash flow | report ↗ |
| 2024-Q2 | — | $3.6M | $8.1M | $5.9M-$6.2M operating cash flow | report ↗ |
| 2024-Q1 | — | $3.8M | $10M | $6.8M-$6.7M operating cash flow | report ↗ |
| 2023-Q3 | — | $3.9M | $19M | $6.3M-$6.2M operating cash flow | report ↗ |
| 2023-Q2 | — | $5.5M | $21M | $8.0M-$4.8M operating cash flow | report ↗ |
| 2023-Q1 | — | $4.2M | $25M | —$4.6M operating cash flow | report ↗ |
| 2022-Q3 | — | $4.5M | $22M | $7.6M-$6.9M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.9M | $29M | —-$3.1M operating cash flow | report ↗ |
| 2022-Q1 | $3.1M | $4.9M | $35M | $7.7M-$5.1M operating cash flow | report ↗ |
| 2021-Q3 | $3.1M | $4.4M | $52M | $7.0M-$5.2M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $15M | $22M | $6.5M-$26M operating cash flow | report ↗ |
Aptevo Therapeutics reported no revenue for FY2025, with prior-year revenue also not disclosed. R&D expense was $14.54M, up 1.1% YoY from $14.38M. Cash and equivalents totaled $21.62M, and the company posted a net loss of $25.97M and a quarterly net burn of $25.97M.
Management stated current resources are expected to support operations into the fourth quarter of 2026, while a $60M equity line facility established in 2026 could, if fully utilized, extend support into 2029. Updated mipletamig data from 28 frontline AML patients showed an 86% clinical benefit rate with no cytokine release syndrome, and the company expanded its CD3 pipeline with three new multispecific candidates, including its first two trispecific assets. Additionally, Marvin White is transitioning to Executive Chair, with Jeff Lamothe assuming the roles of President and Chief Executive Officer.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-06 | Niederhuber John · director | Option exercise | 400 | — | — | Form 4 |
| 2026-08-06 | Kunz Barbara Lopez · director | Option exercise | 400 | — | — | Form 4 |
| 2026-08-06 | Abdun-Nabi Daniel · director | Option exercise | 400 | — | — | Form 4 |
| 2026-08-06 | Grant Grady III · director | Option exercise | 400 | — | — | Form 4 |
| 2026-08-06 | Huebner Dirk · SVP, CMO | Option exercise | 638 | — | — | Form 4 |
| 2026-08-06 | Kwon SoYoung · SVP, GC, BD & Corp Affairs | Option exercise | 638 | — | — | Form 4 |
| 2026-08-06 | Taylor Daphne · SVP, CFO | Option exercise | 638 | — | — | Form 4 |
| 2026-08-06 | Lamothe Jeffrey G. · director, President and CEO | Option exercise | 961 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 9 reporting institutions held 0.1M shares ($146K, 3.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 13,337 | $57K |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 12,713 | $54K |
| 3 | VANGUARD FIDUCIARY TRUST CO | 4,142 | $18K |
| 4 | UBS Group AG | 3,445 | $15K |
| 5 | OSAIC HOLDINGS, INC. | 360 | $2K |
| 6 | SBI Securities Co., Ltd. | 109 | $465 |
| 7 | GSA CAPITAL PARTNERS LLP | 19,638 | $84 |
| 8 | CWM, LLC | 5 | $21 |
| 9 | DANSKE BANK A/S | 1 | $4 |